Can a common arthritis drug tame chikungunya joint pain?
NCT ID NCT04483466
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether methotrexate, a drug used for rheumatoid arthritis, can reduce joint swelling and pain in people with chronic arthritis caused by chikungunya virus. About 150 adults in Colombia will receive either methotrexate or a placebo for 6 months. The goal is to see if the drug improves disease activity scores and reduces inflammation in joint tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Methotrexate (a drug that calms the immune system to reduce joint inflammation)
- What this could lead to
- If it works, this could point toward a simple, affordable treatment for long-term arthritis caused by chikungunya virus.
- What could go wrong
- This is a mid-stage trial with only 150 people, so results may not apply to everyone. Methotrexate can cause side effects like nausea, liver issues, or increased infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC CHIKUNGUNYA ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinica de la Costa
Barranquilla, Colombia